FV-100: Difference between revisions
Content deleted Content added
Updating {{chembox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation |
m r2.7.1) (Robot: Adding fa:افوی-۱۰۰ |
||
| Line 43: | Line 43: | ||
{{antiinfective-drug-stub}} |
{{antiinfective-drug-stub}} |
||
[[fa:افوی-۱۰۰]] |
|||
Revision as of 00:01, 5 April 2012
| |
| Names | |
|---|---|
| IUPAC name
3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2-one
| |
| Other names
Cf1743
| |
| Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| Properties | |
| C22H26N2O5 | |
| Molar mass | 398.459 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
FV-100, also known as Cf1743, is an orally available nucleoside analogue drug[1] with antiviral activity.[2] It may be effective against shingles.[3]
It was discovered in 1999.[4]
Clinical trials
It is in a phase II trial against valaciclovir in patients with herpes zoster.[5]
References
- ^ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009
- ^ McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ , 2010 http://www.dailymail.co.uk/health/article-515969/Thousands-spared-pain-shingles.html,
And at Cardiff University, Chris McGuigan, professor of medicinal chemistry, has developed a new drug for shingles, FV-100, which is doing well in phase I trials. FV 100 looks like it will be very potent (more than 10,000 times as strong as aciclovir), safe and could prevent long-term pain, too. It could be on the market by 2010.
{{citation}}: Missing or empty|title=(help) - ^ Step forward for shingles drug - FV100 Shows structure of FV100
- ^ A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |